Heading Health combines evidence-based mental health care with personalized treatment plans, offering a continuum of in-network services for hard-to-treat conditions. The company provides interventional psychiatric services in its centers, including intramuscular ketamine, Spravato, and TMS, alongside psychiatry and therapy via telehealth. Founded in 2020 by co-founders Steve Levine, MD, and CEO Simon Tankel, Heading operates locations in the Austin and Dallas–Fort Worth metros. It plans further expansion in Dallas and a first location in Houston later this year. Heading intends to use new funding to scale into new markets and to invest in its care delivery and analytics platform. The company recently completed a notable financing round, signaling early-stage investor interest in its in-network, intervention-capable care model.

Total raised

$5M

Funding rounds

1

Latest round

Series A

Latest activity

Jun 2023